Features

Filter by:

  • Nature Biotechnology asks a selection of faculty about the most exciting frontier in their field and the most needed technologies for advancing knowledge and applications.

    • Nasim Annabi
    • Matthew Baker
    • Jianbin Wang
    Feature
  • Investment and funding has continued to flow into biotech, unlike most business sectors. But with healthcare and hospital budgets increasingly under pressure, do belt-tightening and consolidation lie ahead? Melanie Senior investigates, with additional reporting by Riku Lähteenmäki.

    • Melanie Senior
    Feature
  • Our annual survey highlights startups tackling intractable viruses with new vaccine design, engineering a reliable source of platelets, universalizing cell therapies, improving cancer screening, developing RNA-editing platforms and targeting protein–RNA interactions. Michael Eisenstein, Ken Garber, Caroline Seydel and Laura DeFrancesco report.

    • Michael Eisenstein
    • Ken Garber
    • Laura DeFrancesco
    Feature
  • European biotech companies continued to raise unprecedented amounts of capital last year. Can they survive what are likely to be leaner times ahead?

    • Melanie Senior
    Feature
  • China is finally embracing biopharmaceutical innovation, but it is innovation that looks different from that in the West.

    • Brady Huggett
    Feature
  • Public companies continued to ride the crest of the wave of financing, licensing deals and regulatory approvals, but clouds may be looming on the horizon for the biggest biotech players. Chris Morrison and Riku Lähteenmäki report.

    • Chris Morrison
    • Riku Lähteenmäki
    Feature
  • Our annual survey highlights startups taking on gene therapy, adoptive immune cell therapy, gene editing, and drugs targeting RNA modifications and the unfolded protein response. Ken Garber, Esther Landhuis, Melanie Senior, Cormac Sheridan and Laura DeFrancesco report.

    • Ken Garber
    • Esther Landhuis
    • Laura DeFrancesco
    Feature
  • 2018 was the year when the funding machine for privately held biotech companies went into overdrive, with mega-rounds and rapid flotations. John Hodgson brings us this deep dive.

    • John Hodgson
    Feature
  • Monoclonal antibodies (mAbs) continue to reign supreme, although cellular and gene therapies are slowly starting to gather momentum. Burgeoning growth in biosimilars may threaten future brand monopolies for mAbs and other biologics.

    • Gary Walsh
    Feature
  • A group of microbiome researchers discuss some of the challenges in developing a new generation of microbiome therapies.

    • Gaspar Taroncher-Oldenburg
    • Susan Jones
    • Jun Wang
    Feature
  • Last year, investors scrambled to invest in newly floated biotechs. This, together with a brisk licensing market and policy tailwinds, helped boost the sector, even as an expected M&A boom was late to materialize.

    • Chris Morrison
    • Riku Lähteenmäki
    Feature
  • More investors are building companies from scratch, with more money than any time in biotech's history.

    • Brady Huggett
    Feature
  • Our annual survey highlights how immune-oncology and screens based on the application of cutting-edge omics technologies are providing a launchpad for a succession of startups interrogating biology across biomedicine.

    • Malorye Allison Branca
    • Ken Garber
    • Laura DeFrancesco
    Feature
  • Two years after the biotech industry was called out on gender imbalance, the lack of racial diversity in the workforce is largely being ignored.

    • Brady Huggett
    Feature
  • Regulators, scientists and surgeons are preparing the groundwork for human trials of engineered pig organs—and industry is starting to take notice.

    • Emily Waltz
    Feature
  • Is it time to reassess the 14-day rule for human embryo research?

    • J Benjamin Hurlbut
    • Insoo Hyun
    • Laurie Zoloth
    Feature
  • The anticipated decline in the biotech industry's ability to raise capital from public investors and an accompanying slump in biotech markets materialized in 2016, but all is not gloom and doom.

    • Chris Morrison
    • Riku Lähteenmäki
    Feature